Glycosaminoglycan (GAG) binding surfaces for characterizing GAG-protein interactions

Biomaterials

Volumn 33, Issue 4, 2012, Pages 1007-1016

  Robinson, David E ^a,b   Buttle, David J ^a   Short, Robert D ^c   McArthur, Sally L ^d   Steele, David A ^c   Whittle, Jason D ^c,e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^e Innovation Centre   (United Kingdom)

Author keywords

ELISA; Glycosaminoglycan; Osteoprotegerin; Plasma polymerisation; Tissue inhibitor of metalloproteinase 3; Tumor necrosis factor stimulated gene 6

Indexed keywords

ELISA; GLYCOSAMINOGLYCANS; OSTEOPROTEGERIN; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR NECROSIS FACTOR-STIMULATED GENE-6;

GENES; PEPTIDES; PLASMA POLYMERIZATION; SCAFFOLDS; TISSUE;

SCAFFOLDS (BIOLOGY);

GLYCOSAMINOGLYCAN; OSTEOPROTEGERIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE SCAFFOLD;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; SULFATION; TISSUE ENGINEERING;

GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; OSTEOPROTEGERIN; POLYMERIZATION; PROTEIN BINDING; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 81455153960     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.042     Document Type: Article

References (68)

1. Mulloy B., Rider C.C. Cytokines and proteoglycans: an introductory overview. Biochem Soc Trans 2006, 34:409-413.
2. Mulloy B., Forster M.J. Conformation and dynamics of heparin and heparan sulfate. Glycobiology 2000, 10(11):1147-1156.
3. Sasisekharan R., Raman R., Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annu Rev Biomed Eng 2006, 8:181-231.
4. Ikeda Y., Charef S., Ouidja M.O., Barbier-Chassefiere V., Sineriz F., Duchesnay A., et al. Synthesis and biological activities of a library of glycosaminoglycans mimetic oligosaccharides. Biomaterials 2011, 32(3):769-776.
5. Wang W., Xu G.L., Jia W.D., Ma J.L., Li J.S., Ge Y.S., et al. Ligation of TLR2 by Versican: a link between inflammation and Metastasis. Arch Med Res 2009, 40(4):321-323.
6. Rapraeger A.C. Syndecan-regulated receptor signaling. J Cell Biol 2000, 149(5):995-997.
7. Knox S.M., Whitelock J.M. Perlecan: how does one molecule do so many things?. Cell Mol Life Sci 2006, 63(21):2435-2445.
8. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. Febs J 2010, 277(19):3864-3875.
9. Iozzo R.V. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 2001, 108(2):165-167.
10. Kreuger J., Jemth P., Sanders-Lindberg E., Eliahu L., Ron D., Basilico C., et al. Fibroblast growth factors share binding sites in heparan sulphate. Biochem J 2005, 389:145-150.
11. Marson A., Robinson D.E., Brookes P.N., Mulloy B., Wiles M., Clark S.J., et al. Development of a microtiter plate-based glycosaminoglycan array for the investigation of glycosaminoglycan-protein interactions. Glycobiology 2009, 19(12):1537-1546.
12. Robinson D.E., Marson A., Short R.D., Buttle D.J., Day A.J., Parry K.L., et al. Surface gradient of functional heparin. Adv Mater 2008, 20(6):1166-1169.
13. Ward A.J., Short R.D. A TOF-SIMS and XPSinvestigation of the structure of plasma polymers prepared from the methacrylate series of monomers.2. The influence of the W/F parameter on structural and functional-group retention. Polymer 1995, 36(18):3439-3450.
14. Ward A.J., Short R.D. A time-of-flight secondary-ion mass-spectrometry and x-ray photoelectron-spectroscopy investigation of the structure of plasma polymers prepared from the methacrylate series of monomers. Polymer 1993, 34(20):4179-4185.
15. Rinsch C.L., Chen X.L., Panchalingam V., Eberhart R.C., Wang J.H., Timmons R.B. Pulsed radio frequency plasma polymerization of allyl alcohol: controlled deposition of surface hydroxyl groups. Langmuir 1996, 12(12):2995-3002.
16. Beck A.J., Candan S., Short R.D., Goodyear A., Braithwaite N.S.J. The role of ions in the plasma polymerization of allylamine. J Phys Chem B 2001, 105(24):5730-5736.
17. Barry J.J.A., Silva M., Shakesheff K.M., Howdle S.M., Alexander M.R. Using plasma deposits to promote cell population of the porous interior of three-dimensional poly(D, L-lactic acid) tissue-engineering scaffolds. Adv Func Mate 2005, 15(7):1134-1140.
18. Shard A.G., Whittle J.D., Beck A.J., Brookes P.N., Bullett N.A., Talib R.A., et al. A NEXAFS examination of unsaturation in plasma polymers of allylamine and propylamine. J Phys Chem B 2004, 108(33):12472-12480.
19. Chatelier R.C., Hodges A.M., Drummond C.J., Chan D.Y.C., Griesser H.J. Determination of the intrinsic acid-base dissociation constant and site density of ionizable surface groups by capillary rise measurements. Langmuir 1997, 13(11):3043-3046.
20. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15(6):457-475.
21. Holen I., Croucher P.I., Hamdy F.C., Eaton C.L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002, 62(6):1619-1623.
22. Holen I., Cross S.S., Neville-Webbe H.L., Cross N.A., Balasubramanian S.P., Croucher P.I., et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival?. Breast Cancer Res Treat 2005, 92(3):207-215.
23. Theoleyre S., Tat S.K., Vusio P., Blanchard F., Gallagher J., Ricard-Blum S., et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappa B ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006, 347(2):460-467.
24. Lee M.H., Atkinson S., Murphy G. Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem 2007, 282(9):6887-6898.
25. Rapti M., Atkinson S.J., Lee M.H., Trim A., Moss M., Murphy G. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochem J 2008, 411:433-439.
26. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. Febs Lett 1998, 435(1):39-44.
27. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001, 276(16):12501-12504.
28. Shen Y., Winkler I.G., Barbier V., Sims N.A., Hendy J., Levesque J.-P. Tissue inhibitor of metalloproteinase-3 (TIMP-3) regulates hematopoiesis and bone formation. In-Vivo Plos One 2010, 5(9).
29. Saito A., Munakata H. Analysis of plasma proteins that bind to glycosaminoglycans. Biochim Biophys Acta 2007, 1770(2):241-246.
30. MacNeil S. Progress and opportunities for tissue-engineered skin. Nature 2007, 445(7130):874-880.
31. Yasuda H.K. Plasma polymerization 1985, Academic Press, London.
32. Short R.D., Steele D.A. Testing the Hypothesis: comments on plasma polymerisation of acrylic acid revisited. Plasma Processes Polym 2010, 7(5):366-370.
33. Mulloy B., Gray E., Barrowcliffe T.W. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost 2000, 84(6):1052-1056.
34. Casu B., Johnson E.A., Mantovani M., Mulloy B., Oreste P., Pescador R., et al. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulfates. Arzneimittel-Forschung/Drug Res 1983, 33-1(1):135-142.
35. Parkar A.A., Day A.J. Overlapping sites on the Link module of human TSG-6 mediate binding to hyaluronan and chondroitin-4-sulphate. Febs Lett 1997, 410(2-3):413-417.
36. Pavao M.S.G., Mourao P.A.S., Mulloy B., Tollefsen D.M. A unique dermatan sulfate-like glycosaminoglycan from ascidian - its structure and the effect of its unusual sulfation pattern on anticoagulant activity. J Biol Chem 1995, 270(52):31027-31036.
37. Clark S.J., Higman V.A., Mulloy B., Perkins S.J., Lea S.M., Sim R.B., et al. His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem 2006, 281(34):24713-24720.
38. Parkar A.A., Kahmann J.D., Howat S.L.T., Bayliss M.T., Day A.J. TSG-6 interacts with hyaluronan and aggrecan in a pH-dependent manner via a common functional element: implications for its regulation in inflamed cartilage. Febs Lett 1998, 428(3):171-176.
39. Getting S.J., Mahoney D.J., Cao T., Rugg M.S., Fries E., Milner C.M., et al. The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha-inhibitor-independent manner. J Biol Chem 2002, 277(52):51068-51076.
40. Milner C.M., Day A.J. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci 2003, 116(10):1863-1873.
41. Mahoney D.J., Whittle J.D., Milner C.M., Clark S.J., Mulloy B., Buttle D.J., et al. A method for the non-covalent immobilization of heparin to surfaces. Anal Biochem 2004, 330(1):123-129.
42. Mahoney D.J., Blundell C.D., Day A.J. Mapping the hyaluronan-binding site on the link module from human tumor necrosis factor-stimulated gene-6 by site-directed mutagenesis. J Biol Chem 2001, 276(25):22764-22771.
43. Whittle J.D., Short R.D., Douglas C.W.I., Davies J. Differences in the aging of allyl alcohol, acrylic acid, allylamine, and octa-1,7-diene plasma polymers as studied by X-ray photoelectron spectroscopy. Chem Mater 2000, 12(9):2664-2671.
44. Gengenbach T.R., Griesser H.J. Aging of 1,3-diaminopropane plasma-deposited polymer films: mechanisms and reaction pathways. J Polym Sci A 1999, 37(13):2191-2206.
45. Gengenbach T.R., Chatelier R.C., Griesser H.J. Correlation of the nitrogen 1s and oxygen 1s XPS binding energies with compositional changes during oxidation of ethylene diamine plasma polymers. Surf Interf Anal 1996, 24(9):611-619.
46. Gengenbach T.R., Chatelier R.C., Griesser H.J. Characterization of the ageing of plasma-deposited polymer films: Global analysis of x-ray photoelectron spectroscopy data. Surf Interf Anal 1996, 24(4):271-281.
47. Butler G.S., Apte S.S., Willenbrock F., Murphy G. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B - Regulation by polyanions. J Biol Chem 1999, 274(16):10846-10851.
48. Raman R., Venkataraman G., Ernst S., Sasisekharan V., Sasisekharan R. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci USA 2003, 100(5):2357-2362.
49. Day A.J., Prestwich G.D. Hyaluronan-binding proteins: Tying up the giant. J Biol Chem 2002, 277(7):4585-4588.
50. Lesley J., Hascall V.C., Tammi M., Hyman R. Hyaluronan binding by cell surface CD44. J Biol Chem 2000, 275(35):26967-26975.
51. Ye S., Luo Y.D., Lu W.Q., Jones R.B., Linhardt R.J., Capila I., et al. Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochemistry 2001, 40(48):14429-14439.
52. Mei Y., Saha K., Bogatyrev S.R., Yang J., Hook A.L., Kalcioglu Z.I., et al. Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat Mater 2010, 9(9):768-778.
53. van Os M.T., Menges B., Forch R., Knoll W., Timmons R.B., Vancso G.J. Thin film plasma deposition of allylamine; Effects of solvent treatment. Plasma Deposition Treat Polym 1999, 544:45-50.
54. Calderon J.G., Harsch A., Gross G.W., Timmons R.B. Stability of plasma-polymerized allylamine films with sterilization by autoclaving. J Biomed Mater Res 1998, 42(4):597-603.
55. France R.M., Short R.D., Dawson R.A., MacNeil S. Attachment of human keratinocytes to plasma co-polymers of acrylic acid octa-1,7-diene and allyl amine octa-1,7-diene. J Mat Chem 1998, 8(1):37-42.
56. France R.M., Short R.D., Duval E., Jones F.R., Dawson R.A., MacNeil S. Plasma copolymerization of allyl alcohol 1,7-octadiene: surface characterization and attachment of human keratinocytes. Chem Mater 1998, 10(4):1176-1183.
57. Daw R., Brook I.M., Devlin A.J., Short R.D., Cooper E., Leggett G.J. A comparative study of cell attachment to self assembled monolayers and plasma polymers. J Mater Chem 1998, 8(12):2583-2584.
58. Whittle J.D., Bullett N.A., Short R.D., Douglas C.W.I., Hollander A.P., Davies J. Adsorption of vitronectin, collagen and immunoglobulin-G to plasma polymer surfaces by enzyme linked immunosorbent assay (ELISA). J Mater Chem 2002, 12(9):2726-2732.
59. Harsch A., Calderon J., Timmons R.B., Gross G.W. Pulsed plasma deposition of allylamine on polysiloxane: a stable surface for neuronal cell adhesion. J Neurosci Methods 2000, 98(2):135-144.
60. Bullett N.A., Whittle J.D., Short R.D., Douglas C.W.I. Adsorption of immunoglobulin G to plasma-co-polymer surfaces of acrylic acid and 1,7-octadiene. J Mater Chem 2003, 13(7):1546-1553.
61. Buijs J., vandenBerg P.A.W., vandenBerg P.A.W., Lichtenbelt J.W.T., Norde W., Lyklema J. Adsorption dynamics of IgG and its F(ab')(2) and Fc fragments studied by reflectometry. J Colloid Interface Sci 1996, 178(2):594-605.
62. Mahoney D.J., Mulloy B., Forster M.J., Blundell C.D., Fries E., Milner C.M., et al. Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin - implications for the inhibition of plasmin in extracellular matrix microenvironments. J Biol Chem 2005, 280(29):27044-27055.
63. Higman V.A., Blundell C.D., Mahoney D.J., Redfield C., Noble M.E.M., Day A.J. Plasticity of the TSG-6 HA-binding loop and mobility in the TSG-6-HA complex revealed by NMR and X-ray crystallography. J Mol Biol 2007, 371(3):669-684.
64. Saito A., Munakata H. Factor H is a dermatan sulfate-binding protein: identification of a dermatan sulfate-mediated protease that cleaves factor H. J Biochem 2005, 137(2):225-233.
65. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15(1):2-12.
66. Hsu H.L., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96(7):3540-3545.
67. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273(23):14363-14367.
68. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003, 9(4):407-415.